
Zimbabwe

African Region



I. Epidemiological profile

Population (UN Population Division)	2023	%
High transmission (>1 case per 1000 population)	4.7M	29
Low transmission (0-1 case per 1000 population)	8.2M	50
Malaria free (0 cases)	3.5M	21
Total	16.3M	

Parasites and vectors $\label{thm:major_plasmodium} \mbox{Major plasmodium species (indigenous cases):}$ P. falciparum: 100 (%)*, P. vivax: 0 (%) Major anopheles species: An. arabiensis, An. gambiae s.s., An. funestus s.s. *includes mixed infections and other species of Plasmodium

Reported cases and deaths	
Presumed and confirmed cases	248 699
Reported indigenous confirmed cases:	246 154
Confirmed cases from public sector:	100 380
Confirmed cases from private sector:	3030
Confirmed cases at community level:	145 289
Confirmed cases in combined health sectors:	-
Indigenous deaths:	317

Estimates	
Estimated cases:	635.6K [381.2K, 913.7K]
Estimated deaths:	1.6K [601, 3.1K]

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/ No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2006
	ITN distributed by mass campaign	Yes	2010
IRS	IRS is recommended	Yes	-
	DDT is used for IRS	Yes	1974
Larval control	Use of Larval Control	Yes	2012
IPT	IPT used to prevent malaria during pregnancy	Yes	2004
Diagnosis	Malaria diagnosis using RDT is free of charge in the public sector	Yes	2009
	Malaria diagnosis using microscopy is free of charge in the public sector	Yes	2009
	Malaria diagnosis is free in the private sector	No	-
Treatment	ACT is free for all ages in public sector	Yes	2008
	The sale of oral artemisinin-based monotherapies (oAMTs)	banned	2004
	Single low dose of primaquine (0.75 mg base/kg) with ACT to reduce transmissibility of <i>P. falciparum</i>	Yes*	2015
	Primaquine is used for radical treatment of P. vivax	NA	-
	G6PD test is a requirement before treatment with primaquine	NA	-
	Directly observed treatment with primaquine is undertaken	NA	-
	System for monitoring of adverse reaction to antimalarials exists	Yes	2010
Surveillance	Malaria is a notifiable disease	Yes	2012
	ACD for case investigation (reactive)	Yes*	-
	ACD at community level of febrile cases (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	No	-
	Uncomplicated P. vivax cases routinely admitted	No	-
	Case investigation undertaken	Yes	2012
	Foci investigation undertaken	Yes	2017
	Case reporting from private sector is mandatory	No	-
		_	

Yes* = Policy adopted	, but not implemented	in 2023

Disc = Discontinued

Earliest year that policy is adopted was adjusted based on the earliest year that the WHO policy was recommended

Antimalaria	treatment pol	licy				Medicine	Year adopted
First-line treatment of unconfirmed malaria					NA	-	
First-line tre	eatment of P. f	alciparı	ım			AL	2004
Second-line	treatment P. I	falcipar	um			AS+AQ	2015
Treatment of	f severe mala	ria				AS	2012
Treatment of	f <i>P. vivax</i>					NA	-
Dosage of p	rimaquine for	radical	treatmen	t of <i>P. v</i>	ivax	0.	25 mg/Kg (14 days)
Type of RDT	used (public)						P.f only
Therapeutic	efficacy tests	(clinica	l and para	sitolog	ical failure, %)		
Medicine	Year		Median	Max	Follow-up	No. of studies	Species
AL	2017-2017	0	0	4.8	28 days	5	P. falciparum
		ticide c				ss for malaria vect	
Insecticide	class		(%) sites ¹		Vector	rs²	Used ³
Carbamates							No
Neonicotinoids			0% (0/2)				Yes
Organophosphates Pyrethroids			0% (0/7) 33% (3/9)		An. gambiae s.l.		No Yes
¹ Percent of sit ² Vectors repor	ted to exhibit res	istance to	confirmed ar	nd total r	number of sites th	at reported data	evious year were used)







→ Indigenous malaria cases

Estimated cases









Source: DHS 2011,2015

Confirmed malaria cases per 1000 population at risk and ABER




Malaria inpatients and deaths



ABER=smears examined in a year X100 / Total population. Includes cases that are imported and introduced

٧. Coverage of ITN and IRS 100 75 8 50 % population that has access to ITNs (Modelled) → At risk protected with IRS % of the population who slept under an ITN the previous night(survey) % of the population with access to an ITN(survey)





Source: DHS 2011,2015

VI. Government expenditure by intervention in 2023



Footnotes (est.): WHO estimates based on the survey

Country profiles are generated automatically based on data reported by countries. They are available for all current malaria endemic countries and territories asked to report to the Global Malaria Programme annually. Country profiles are based on data validated by the countries as of 14 November 2024.

Further information on the methods used to estimate malaria cases and an explanation for the gap between estimated and reported confirmed indigenous cases is provided majorage-april/2018-erg-report-malaria-burden-session6.pdf (who.int)